Nicholas Fidelman, MD
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases (NCT03457948) | Nicholas Fidelman, MD | 2018-08-27 |
Track Nicholas Fidelman, MD automatically
Every clearance here is in the API, with alerts when new ones post.